20160501 CCMG-CCGM - Poster Presentations - Part 1

Interactive session with the authors of poster presentations.

MG-100 Case Report: Two pregnancies in a patient with maple syrup urine disease
Dr. Shailly Jain, Stollery Children's Hospital

MG-101 Putative association of a germline mutation in HYOU1 with nephrosclerosis and end-stage renal disease.
Dr. Karen Bedard, Dalhousie University

MG-102 Profile of genetic variants identified in patients with connective tissue disorders using a targeted next generation sequencing platform
Dr. Catherine Fen Li, Calgary Laboratory Services

MG-103 Experience with a targeted next generatiothurn sequencing platform in patients with autism spectrum disorders
Dr. Catherine Fen Li, Calgary Laboratory Services

MG-104 HER2 amplification status in breast cancer: assessing the impacts caused by implantation of ASCO/CAP (2013) guidelines in clinical setting.
Dr. Flechere Fortin, CIUSSS - CHUS

MG-105 PGxome: Leveraging the power of many for whole exome sequencing
Dr. Diane Allingham-Hawkins, Calgary Laboratory Services

MG-106 Sexual dimorphism in SMAD3 mutation carriers: implications for management derived from a large family.
Dr. Julie Richer, Chidren's Hospital of Eastern Ontario

MG-107 Formation of the Medical Genetics recommendations for Choosing Wisely Canada
Dr. Elaine Goh, Credit Valley Hospital

MG-108 Dystrophin deletions: two cases of incidental, medically actionable results on microarray.
Dr. Victoria Siu, London Health Sciences Centre

MG-109 H3.1 K36 mutation in a congenital-onset soft tissue neoplasm
Dr. Sarah Sawyer, Children's Hospital of Eastern Ontario

MG-110 Clinical validation of PhenoVar as a diagnostic tool in the interpretation of exome sequencing for genetic disorders
Mrs. Fanny Thuriot, Université de Sherbrooke

MG-111 Naxos disease in French-Canadian families with a novel founder mutation
Dr. Tania Cruz Marinoa, CIUSSS

MG-112 17q25.3 duplication in a patient with psychosis and autism spectrum disorder, further support for this novel psychiatric illness susceptibility locus
Ms Kellie MacDonald, McGill University

MG-113 Inherited Tatton-Brown-Rahman syndrome due to novel DNMT3A germline mutations in French Canadian and Old Order Amish families
Dr. Tania Cruz Marinoa, CIUSSS

Question Title

* 1. Please Rate Each Session:

	Did Not Attend	Poor	Fair	Good	Very Good	Excellent
MG-100 Case Report: Two pregnancies in a patient with maple syrup urine disease	MG-100 Case Report: Two pregnancies in a patient with maple syrup urine disease Did Not Attend	MG-100 Case Report: Two pregnancies in a patient with maple syrup urine disease Poor	MG-100 Case Report: Two pregnancies in a patient with maple syrup urine disease Fair	MG-100 Case Report: Two pregnancies in a patient with maple syrup urine disease Good	MG-100 Case Report: Two pregnancies in a patient with maple syrup urine disease Very Good	MG-100 Case Report: Two pregnancies in a patient with maple syrup urine disease Excellent
MG-101 Putative association of a germline mutation in HYOU1 with nephrosclerosis and end-stage renal disease.	MG-101 Putative association of a germline mutation in HYOU1 with nephrosclerosis and end-stage renal disease. Did Not Attend	MG-101 Putative association of a germline mutation in HYOU1 with nephrosclerosis and end-stage renal disease. Poor	MG-101 Putative association of a germline mutation in HYOU1 with nephrosclerosis and end-stage renal disease. Fair	MG-101 Putative association of a germline mutation in HYOU1 with nephrosclerosis and end-stage renal disease. Good	MG-101 Putative association of a germline mutation in HYOU1 with nephrosclerosis and end-stage renal disease. Very Good	MG-101 Putative association of a germline mutation in HYOU1 with nephrosclerosis and end-stage renal disease. Excellent
MG-102 Profile of genetic variants identified in patients with connective tissue disorders using a targeted next generation sequencing platform	MG-102 Profile of genetic variants identified in patients with connective tissue disorders using a targeted next generation sequencing platform Did Not Attend	MG-102 Profile of genetic variants identified in patients with connective tissue disorders using a targeted next generation sequencing platform Poor	MG-102 Profile of genetic variants identified in patients with connective tissue disorders using a targeted next generation sequencing platform Fair	MG-102 Profile of genetic variants identified in patients with connective tissue disorders using a targeted next generation sequencing platform Good	MG-102 Profile of genetic variants identified in patients with connective tissue disorders using a targeted next generation sequencing platform Very Good	MG-102 Profile of genetic variants identified in patients with connective tissue disorders using a targeted next generation sequencing platform Excellent
MG-103 Experience with a targeted next generatiothurn sequencing platform in patients with autism spectrum disorders	MG-103 Experience with a targeted next generatiothurn sequencing platform in patients with autism spectrum disorders Did Not Attend	MG-103 Experience with a targeted next generatiothurn sequencing platform in patients with autism spectrum disorders Poor	MG-103 Experience with a targeted next generatiothurn sequencing platform in patients with autism spectrum disorders Fair	MG-103 Experience with a targeted next generatiothurn sequencing platform in patients with autism spectrum disorders Good	MG-103 Experience with a targeted next generatiothurn sequencing platform in patients with autism spectrum disorders Very Good	MG-103 Experience with a targeted next generatiothurn sequencing platform in patients with autism spectrum disorders Excellent
MG-104 HER2 amplification status in breast cancer: assessing the impacts caused by implantation of ASCO/CAP (2013) guidelines in clinical setting.	MG-104 HER2 amplification status in breast cancer: assessing the impacts caused by implantation of ASCO/CAP (2013) guidelines in clinical setting. Did Not Attend	MG-104 HER2 amplification status in breast cancer: assessing the impacts caused by implantation of ASCO/CAP (2013) guidelines in clinical setting. Poor	MG-104 HER2 amplification status in breast cancer: assessing the impacts caused by implantation of ASCO/CAP (2013) guidelines in clinical setting. Fair	MG-104 HER2 amplification status in breast cancer: assessing the impacts caused by implantation of ASCO/CAP (2013) guidelines in clinical setting. Good	MG-104 HER2 amplification status in breast cancer: assessing the impacts caused by implantation of ASCO/CAP (2013) guidelines in clinical setting. Very Good	MG-104 HER2 amplification status in breast cancer: assessing the impacts caused by implantation of ASCO/CAP (2013) guidelines in clinical setting. Excellent
MG-105 PGxome: Leveraging the power of many for whole exome sequencing	MG-105 PGxome: Leveraging the power of many for whole exome sequencing Did Not Attend	MG-105 PGxome: Leveraging the power of many for whole exome sequencing Poor	MG-105 PGxome: Leveraging the power of many for whole exome sequencing Fair	MG-105 PGxome: Leveraging the power of many for whole exome sequencing Good	MG-105 PGxome: Leveraging the power of many for whole exome sequencing Very Good	MG-105 PGxome: Leveraging the power of many for whole exome sequencing Excellent
MG-106 Sexual dimorphism in SMAD3 mutation carriers: implications for management derived from a large family.	MG-106 Sexual dimorphism in SMAD3 mutation carriers: implications for management derived from a large family. Did Not Attend	MG-106 Sexual dimorphism in SMAD3 mutation carriers: implications for management derived from a large family. Poor	MG-106 Sexual dimorphism in SMAD3 mutation carriers: implications for management derived from a large family. Fair	MG-106 Sexual dimorphism in SMAD3 mutation carriers: implications for management derived from a large family. Good	MG-106 Sexual dimorphism in SMAD3 mutation carriers: implications for management derived from a large family. Very Good	MG-106 Sexual dimorphism in SMAD3 mutation carriers: implications for management derived from a large family. Excellent
MG-107 Formation of the Medical Genetics recommendations for Choosing Wisely Canada	MG-107 Formation of the Medical Genetics recommendations for Choosing Wisely Canada Did Not Attend	MG-107 Formation of the Medical Genetics recommendations for Choosing Wisely Canada Poor	MG-107 Formation of the Medical Genetics recommendations for Choosing Wisely Canada Fair	MG-107 Formation of the Medical Genetics recommendations for Choosing Wisely Canada Good	MG-107 Formation of the Medical Genetics recommendations for Choosing Wisely Canada Very Good	MG-107 Formation of the Medical Genetics recommendations for Choosing Wisely Canada Excellent
MG-108 Dystrophin deletions: two cases of incidental, medically actionable results on microarray.	MG-108 Dystrophin deletions: two cases of incidental, medically actionable results on microarray. Did Not Attend	MG-108 Dystrophin deletions: two cases of incidental, medically actionable results on microarray. Poor	MG-108 Dystrophin deletions: two cases of incidental, medically actionable results on microarray. Fair	MG-108 Dystrophin deletions: two cases of incidental, medically actionable results on microarray. Good	MG-108 Dystrophin deletions: two cases of incidental, medically actionable results on microarray. Very Good	MG-108 Dystrophin deletions: two cases of incidental, medically actionable results on microarray. Excellent
MG-109 H3.1 K36 mutation in a congenital-onset soft tissue neoplasm	MG-109 H3.1 K36 mutation in a congenital-onset soft tissue neoplasm Did Not Attend	MG-109 H3.1 K36 mutation in a congenital-onset soft tissue neoplasm Poor	MG-109 H3.1 K36 mutation in a congenital-onset soft tissue neoplasm Fair	MG-109 H3.1 K36 mutation in a congenital-onset soft tissue neoplasm Good	MG-109 H3.1 K36 mutation in a congenital-onset soft tissue neoplasm Very Good	MG-109 H3.1 K36 mutation in a congenital-onset soft tissue neoplasm Excellent
MG-110 Clinical validation of PhenoVar as a diagnostic tool in the interpretation of exome sequencing for genetic disorders	MG-110 Clinical validation of PhenoVar as a diagnostic tool in the interpretation of exome sequencing for genetic disorders Did Not Attend	MG-110 Clinical validation of PhenoVar as a diagnostic tool in the interpretation of exome sequencing for genetic disorders Poor	MG-110 Clinical validation of PhenoVar as a diagnostic tool in the interpretation of exome sequencing for genetic disorders Fair	MG-110 Clinical validation of PhenoVar as a diagnostic tool in the interpretation of exome sequencing for genetic disorders Good	MG-110 Clinical validation of PhenoVar as a diagnostic tool in the interpretation of exome sequencing for genetic disorders Very Good	MG-110 Clinical validation of PhenoVar as a diagnostic tool in the interpretation of exome sequencing for genetic disorders Excellent
MG-111 Naxos disease in French-Canadian families with a novel founder mutation	MG-111 Naxos disease in French-Canadian families with a novel founder mutation Did Not Attend	MG-111 Naxos disease in French-Canadian families with a novel founder mutation Poor	MG-111 Naxos disease in French-Canadian families with a novel founder mutation Fair	MG-111 Naxos disease in French-Canadian families with a novel founder mutation Good	MG-111 Naxos disease in French-Canadian families with a novel founder mutation Very Good	MG-111 Naxos disease in French-Canadian families with a novel founder mutation Excellent
MG-112 17q25.3 duplication in a patient with psychosis and autism spectrum disorder, further support for this novel psychiatric illness susceptibility locus	MG-112 17q25.3 duplication in a patient with psychosis and autism spectrum disorder, further support for this novel psychiatric illness susceptibility locus Did Not Attend	MG-112 17q25.3 duplication in a patient with psychosis and autism spectrum disorder, further support for this novel psychiatric illness susceptibility locus Poor	MG-112 17q25.3 duplication in a patient with psychosis and autism spectrum disorder, further support for this novel psychiatric illness susceptibility locus Fair	MG-112 17q25.3 duplication in a patient with psychosis and autism spectrum disorder, further support for this novel psychiatric illness susceptibility locus Good	MG-112 17q25.3 duplication in a patient with psychosis and autism spectrum disorder, further support for this novel psychiatric illness susceptibility locus Very Good	MG-112 17q25.3 duplication in a patient with psychosis and autism spectrum disorder, further support for this novel psychiatric illness susceptibility locus Excellent
MG-113 Inherited Tatton-Brown-Rahman syndrome due to novel DNMT3A germline mutations in French Canadian and Old Order Amish families	MG-113 Inherited Tatton-Brown-Rahman syndrome due to novel DNMT3A germline mutations in French Canadian and Old Order Amish families Did Not Attend	MG-113 Inherited Tatton-Brown-Rahman syndrome due to novel DNMT3A germline mutations in French Canadian and Old Order Amish families Poor	MG-113 Inherited Tatton-Brown-Rahman syndrome due to novel DNMT3A germline mutations in French Canadian and Old Order Amish families Fair	MG-113 Inherited Tatton-Brown-Rahman syndrome due to novel DNMT3A germline mutations in French Canadian and Old Order Amish families Good	MG-113 Inherited Tatton-Brown-Rahman syndrome due to novel DNMT3A germline mutations in French Canadian and Old Order Amish families Very Good	MG-113 Inherited Tatton-Brown-Rahman syndrome due to novel DNMT3A germline mutations in French Canadian and Old Order Amish families Excellent

Question Title

* 2. Please assess the Sessions as a whole

	Strongly Disagree	Disagree	Neutral	Agree	Strongly Agree
Sufficient time was allowed for audience participation/active learning	Sufficient time was allowed for audience participation/active learning Strongly Disagree	Sufficient time was allowed for audience participation/active learning Disagree	Sufficient time was allowed for audience participation/active learning Neutral	Sufficient time was allowed for audience participation/active learning Agree	Sufficient time was allowed for audience participation/active learning Strongly Agree
The facilities were satisfactory	The facilities were satisfactory Strongly Disagree	The facilities were satisfactory Disagree	The facilities were satisfactory Neutral	The facilities were satisfactory Agree	The facilities were satisfactory Strongly Agree
The session was free from commercial bias	The session was free from commercial bias Strongly Disagree	The session was free from commercial bias Disagree	The session was free from commercial bias Neutral	The session was free from commercial bias Agree	The session was free from commercial bias Strongly Agree
Overall, I would rate this Symposium as excellent	Overall, I would rate this Symposium as excellent Strongly Disagree	Overall, I would rate this Symposium as excellent Disagree	Overall, I would rate this Symposium as excellent Neutral	Overall, I would rate this Symposium as excellent Agree	Overall, I would rate this Symposium as excellent Strongly Agree

Question Title

* 3. As a result of attending these sessions, I am planning to:

a) Discuss the session with my colleagues

b) Pursue additional learning activities.

c) Complete a Personal Learning Project.

d) Not change my practice.

e) Change my practice.

Question Title

* 4. Please explain any changes you plan to make or personal learning projects you will pursue as a result of this session:

Question Title

* 5. Please indicate which CanMEDS roles you felt were addressed during this educational activity. (Select all that apply)

Medical Expert

Communicator

Collaborator

Manager

Health Advocate

Scholar

Professional

20160501 CCMG-CCGM - Poster Presentations - Part 1

Interactive session with the authors of poster presentations.

Question Title

* 1. Please Rate Each Session:

Question Title

* 2. Please assess the Sessions as a whole

Question Title

* 3. As a result of attending these sessions, I am planning to:

Question Title

* 4. Please explain any changes you plan to make or personal learning projects you will pursue as a result of this session:

Question Title

* 5. Please indicate which CanMEDS roles you felt were addressed during this educational activity. (Select all that apply)

Question Title

* 6. General comments about individual speakers:

Question Title

* 7. What topics would you like to be addressed at future conferences to keep you up to date in your profession?